Decheng Capital Global Life Sciences Fund V, L.P.
Raised
$452M
Investors
42
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
Decheng Capital Global Life Sciences Fund V, L.P. is a Cayman Islands-domiciled pooled investment fund that has raised $452.0M from 42 investors under Regulation D exemptions 506(b) and 3(c)(1). This amended filing reports capital raised by the fifth vehicle in the Decheng Capital life sciences franchise, with Xiangmin Cui and Yuheng Qiu listed as directors and Decheng Capital Management V (Cayman), LLC serving as promoter.
This fund represents a substantial institutional raise in the longevity and biotech category, utilizing the private 506(b) exemption typical for venture and growth funds in this sector. The $10.8M average commitment per investor and Cayman domicile align with standard offshore structures for U.S.-based managers raising capital from tax-exempt and international LPs.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Xiangmin Cui
Director · Grand Cayman, E9
Yuheng Qiu
Director · Grand Cayman, E9
N/A Decheng Capital Management V (Cayman), LLC
Promoter · Grand Cayman, E9
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
